Cart
sales@molnova.com
Bavituximab
CAS No. 648904-28-3
Bavituximab( —— )
Catalog No. M36879 CAS No. 648904-28-3
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 938 | In Stock |
|
| 10MG | 1568 | In Stock |
|
| 25MG | 2337 | In Stock |
|
| 50MG | 3088 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBavituximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth.
-
DescriptionBavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer.
-
In VitroBavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1).Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction.Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells.
-
In VivoSorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo.Animal Model:Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors Dosage:100 μg/mouse (Bavituximab/β2GP1) Administration:Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)Result:Traced phosphatidylserine exposure in vivo in mice with tumors.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number648904-28-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6.?
molnova catalog
related products
-
13(S)-Hydroxyoctadec...
(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid.
-
(±)-Lisofylline
(±)-Lisofylline is an enantiomer-specific, alkyl-substituted methylxanthine, which has specific and potent activity in down-regulating leukocyte activation. (±)-Lisofylline is an anti-inflammatory agent.
-
Manool
Manool, a diterpene from Salvia miltiorrhiza, showed antitumor activity in a mouse melanoma model.Manool caused cell cycle arrest in the G(2)/M phase of cancer cells, reducing the prevention of chromosomal damage and precancerous lesions.
